Join
Live feed
·
PRReleasevia Quantisnow
Jazz Pharmaceuticals plc logo
Zymeworks Inc. logo

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

ByQuantisnow·Wall Street's wire, on your screen.
JAZZ· Jazz Pharmaceuticals plcZYME· Zymeworks Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JAZZ (Jazz Pharmaceuticals plc), ZYME (Zymeworks Inc.) and more on Quantisnow.